EUVIMEDEUVIMED entdecken
Open Access

How I Treat Cytopenias after CAR T-cell Therapy

Tania Jain iD, Timothy S Olson, Frederick L Locke

Blood · 17.02.2023

DOI: 10.1182/blood.2022017415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, online erschienen am 17.02.2023. Verfasst von Tania Jain und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimor…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 56-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing use of chimeric antigen receptor T-cell therapy (CAR-T) has unveiled diverse toxicities warranting specific recognition and management. Cytopenias occurring after CAR-T infusion invariably manifest early (<30 days), commonly are prolonged (30-90 days), and sometimes persist or occur late (>90 days). Variable etiologies of these cytopenias, some of which remain incompletely understood, create clinical conundrums and uncertainties about optimal management strategies. These cytopenias may cause additional sequelae, decreased quality of life, and increased resource utilization. Early cytopenias are typically attributed to lymphodepletion chemotherapy however infections and hyperinflammatory response such as immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome may occur. Early and prolonged cytopenias often correlate with severity of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome. Bone marrow biopsy in patients with prolonged or late cytopenias is important to evaluate for primary disease and secondary marrow neoplasm in both pediatric and adult patients. Commonly cytopenias resolve over time and evidence for effective interventions is often anecdotal. Treatment strategies, which are limited and require tailoring based upon likely underlying etiology, include growth factors, thrombopoietin-receptor agonist, stem cell boost, transfusion support, and abrogation of infection risk. Here we provide our approach, including workup and management strategies, for cytopenias following CAR-T.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsAdultHumansChildImmunotherapy, AdoptiveReceptors, Antigen, T-CellQuality of LifeNeurotoxicity Syndromes

Substanzen

Receptors, Chimeric Antigencell-associated neurotoxicityReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Division of Hematological Malignancies and Bone Marrow Transplantation, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.
  • Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA.
  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.

ORCID-Profile: Tania Jain

Zitieren

APA

Jain, T., Olson, T. S., & Locke, F. L. (2023). How I Treat Cytopenias after CAR T-cell Therapy. Blood. https://doi.org/10.1182/blood.2022017415

Vancouver

Jain T, Olson TS, Locke FL. How I Treat Cytopenias after CAR T-cell Therapy. Blood. 2023. doi:10.1182/blood.2022017415

BibTeX
@article{Jain2023,
  author = {Jain, Tania and Olson, Timothy S and Locke, Frederick L},
  title = {How I Treat Cytopenias after CAR T-cell Therapy},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022017415}
}
Kostenlos starten →